Can I Take Resveratrol with Jardiance (Empagliflozin)?

What Is the Interaction Between Resveratrol and Jardiance?

Resveratrol does not block or accelerate empagliflozin's metabolism in any clinically proven way at normal supplement doses. The more meaningful concern is pharmacodynamic: both agents independently lower blood glucose and blood pressure, so combining them amplifies those effects. A secondary issue is resveratrol's partial CYP3A4 inhibition and UGT modulation, which could marginally slow empagliflozin clearance at very high doses.

How Empagliflozin Works

Empagliflozin blocks the sodium-glucose cotransporter-2 (SGLT2) in the proximal renal tubule, causing roughly 70 g of glucose to be excreted in the urine each day at steady state. In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin 10 mg or 25 mg reduced major adverse cardiovascular events by 14% versus placebo and cut cardiovascular death by 38% [2]. The drug also produces a 3 to 4 mmHg systolic blood-pressure reduction independent of glycemia [3].

How Resveratrol Affects Glucose and Blood Pressure

Resveratrol (3,5,4'-trihydroxystilbene) activates SIRT1 and AMPK, both of which improve insulin sensitivity and reduce hepatic glucose output [4]. A 2018 meta-analysis of 11 randomized controlled trials found resveratrol supplementation significantly reduced fasting blood glucose (weighted mean difference: -9.65 mg/dL, P<0.001) in people with type 2 diabetes [5]. The same compound lowers systolic blood pressure by approximately 1.76 mmHg in a pooled analysis of 17 RCTs, according to findings published in the American Journal of Hypertension [1].

Why Combining Both Matters

Those modest individual reductions add up. A patient stabilized on empagliflozin 25 mg who adds 500 mg/day of resveratrol may experience cumulative glucose lowering sufficient to cause symptomatic hypoglycemia, particularly if they are also using a sulfonylurea or insulin. The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of type 2 diabetes emphasizes reviewing all supplements before adding agents that affect insulin sensitivity [6].

Pharmacokinetic Considerations: CYP3A4 and UGT1A Pathways

Empagliflozin is primarily glucuronidated by UGT1A3, UGT1A8, UGT1A9, and UGT2B7; CYP450 pathways play a minor role. Resveratrol at doses seen in high-dose clinical trials (1,000 to 5,000 mg/day) inhibits CYP3A4, CYP2C9, and UGT1A1 in in-vitro models [7]. Standard OTC doses (150 to 500 mg/day) produce peak plasma concentrations well below the IC50 for meaningful enzyme inhibition, making a clinically significant pharmacokinetic interaction unlikely in typical supplement users.

In-Vitro vs. Real-World Relevance

In-vitro inhibition constants do not automatically translate to in-vivo effects. A pharmacokinetic study published in Drug Metabolism and Disposition demonstrated that even 2,000 mg/day oral resveratrol produces rapid first-pass metabolism to sulfate and glucuronide conjugates, dramatically reducing systemic free concentrations available for enzyme inhibition [8]. At the 150 to 500 mg doses on most supplement labels, systemic free resveratrol is unlikely to reach concentrations sufficient to raise empagliflozin plasma levels significantly.

When Pharmacokinetics Could Matter

Higher-dose resveratrol formulations (micronized or combined with piperine to reduce first-pass metabolism) may achieve elevated plasma concentrations. Piperine itself inhibits UGT enzymes [9]. Patients using enhanced-bioavailability resveratrol products should mention this to their prescriber, because even small increases in empagliflozin exposure could slightly amplify glycosuric and diuretic effects.

The Estrogenic Signal: Should You Worry?

Resveratrol binds estrogen receptor beta (ER-beta) with moderate affinity and ER-alpha with lower affinity [10]. This weak estrogenicity is not expected to alter empagliflozin's mechanism, which is receptor-independent. The clinical concern is narrower: patients with hormone-sensitive cancers or those on aromatase inhibitors should discuss resveratrol with their oncologist separately from any Jardiance-related question.

Empagliflozin itself has no known estrogenic activity. The two drugs do not share an endocrine receptor pathway, so there is no pharmacodynamic interaction through the estrogen axis between them specifically.

Additive Blood-Pressure Lowering: Clinical Context

Empagliflozin reduces systolic blood pressure by 3 to 4 mmHg through osmotic diuresis and sodium loss [3]. Resveratrol's pooled effect is roughly 1.76 mmHg systolic [1]. The arithmetic sum approaches 6 mmHg, which is clinically meaningful in a patient whose blood pressure is already at or near target on antihypertensive therapy. Symptomatic hypotension has been reported with SGLT2 inhibitors when added to existing diuretics or ACE inhibitors, as noted in the Jardiance prescribing information [11].

Patients at Highest Risk for Additive Hypotension

Patients over 65, those on loop diuretics, and those with baseline systolic blood pressure below 110 mmHg carry the highest risk of symptomatic hypotension if they add resveratrol to an existing Jardiance regimen. The prescribing information for empagliflozin specifically flags volume depletion as a risk factor for acute kidney injury [11].

What the Numbers Mean in Practice

A 6 mmHg systolic reduction from two non-prescription-level mechanisms is not trivial. In the SPRINT trial (N=9,361), intensive systolic blood-pressure control to <120 mmHg was associated with a 25% reduction in cardiovascular events but also a higher incidence of syncope and acute kidney injury [12]. Adding resveratrol in a patient already achieving tight blood-pressure control with Jardiance pushes them closer to the hazard zone for those adverse events.

Glucose Lowering: Hypoglycemia Risk Profile

Empagliflozin alone has a low intrinsic hypoglycemia risk because it works downstream of insulin secretion. SGLT2 inhibitors do not cause hypoglycemia as monotherapy in most patients [2]. Resveratrol's SIRT1/AMPK-mediated glucose lowering is also insulin-independent and carries its own low hypoglycemia risk in isolation.

When the Combination Raises Risk

The risk rises when either agent is combined with insulin or a sulfonylurea. A 2020 randomized crossover study in Drug and Chemical Toxicology found that resveratrol 500 mg twice daily significantly potentiated the glucose-lowering effect of metformin and glibenclamide in a rodent model, raising concern about human relevance in polypharmacy scenarios [13]. Patients on Jardiance plus a sulfonylurea who add resveratrol should monitor fasting and postprandial glucose more frequently, at least for the first four to six weeks.

Recognizing Low Blood Sugar on This Combination

Classic hypoglycemia symptoms (tremor, diaphoresis, palpitations) remain the clinical signal to watch. Patients on SGLT2 inhibitors who develop euglycemic diabetic ketoacidosis (euDKA) may not have elevated glucose, so any unexplained nausea or vomiting should prompt a urine ketone check, not just a fingerstick glucose [11].

What Clinical Trials Say About Resveratrol in Type 2 Diabetes

Direct head-to-head studies of resveratrol plus empagliflozin do not yet exist in the published literature. Evidence must be assembled from independent lines of research.

Resveratrol Trials in T2DM

The 2018 systematic review and meta-analysis by Hausenblas et al., covering 11 RCTs (total N=388), found resveratrol reduced HbA1c by a weighted mean difference of -0.10% and fasting glucose by -9.65 mg/dL in type 2 diabetes patients [5]. A smaller 12-week RCT by Movahed et al. (N=66) found 1,000 mg/day resveratrol reduced HbA1c by 0.45% compared with placebo (P<0.001) [14].

SGLT2 Inhibitor Cardiovascular and Renal Data

The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced hospitalization for heart failure by 35% and slowed eGFR decline [2]. The EMPEROR-Reduced trial (N=3,730) confirmed empagliflozin's benefit in heart failure with reduced ejection fraction, cutting the composite of cardiovascular death or hospitalization for heart failure by 25% [15]. Neither trial examined co-administration with supplements.

Practical Guidance: Timing, Dose, and Monitoring

The following step-by-step framework is based on pharmacokinetic half-lives, current guideline recommendations, and the additive-effect data reviewed above. It has not been validated in a prospective trial, and a prescriber should confirm its application to individual patients.

Step 1. Disclose before starting. Tell your prescriber or pharmacist about any resveratrol product, including dose and formulation (standard vs. Micronized vs. Piperine-enhanced), before the first dose.

Step 2. Start resveratrol low. If your prescriber approves, begin at 150 to 250 mg/day rather than the 500 to 1,000 mg doses used in some RCTs. Empagliflozin's half-life is about 12.4 hours [11]; resveratrol's free half-life is roughly 1 to 3 hours [8]. There is no pharmacokinetic rationale for dose separation, but starting low lets you detect additive effects before committing to a higher dose.

Step 3. Monitor blood pressure. Check blood pressure at home for the first two weeks. If systolic readings consistently drop below 100 mmHg, contact your prescriber.

Step 4. Monitor glucose. If you use a glucometer, check fasting glucose on waking for the first four weeks. Target fasting glucose for most adults with type 2 diabetes is 80 to 130 mg/dL per ADA Standards of Care 2024 [16].

Step 5. Recheck HbA1c at the next scheduled visit. If HbA1c has dropped more than 0.5% below the previous value without a change in Jardiance dose, your prescriber may consider a dose review.

Step 6. Stop resveratrol if symptoms develop. Dizziness on standing, persistent nausea, or unexplained fatigue warrant a pause and a call to your prescriber, not a wait-and-see approach.

Special Populations

Patients With Heart Failure

Empagliflozin is FDA-approved for heart failure with reduced and preserved ejection fraction [11]. Resveratrol has shown some pre-clinical cardioprotective effects through SIRT1 activation, but large-scale heart failure trials of resveratrol do not exist. Patients with heart failure are often on multiple medications, including diuretics and ACE inhibitors, making the additive blood-pressure effect more clinically significant.

Patients With Chronic Kidney Disease

The FDA approved empagliflozin for CKD in 2023, based on the EMPA-KIDNEY trial (N=6,609), which showed a 28% relative risk reduction in kidney disease progression or cardiovascular death [17]. Resveratrol is renally cleared; dose adjustment in CKD has not been formally studied. Patients with eGFR below 30 mL/min/1.73m² should avoid high-dose resveratrol until data exist.

Patients With Hormone-Sensitive Conditions

Resveratrol's ER-beta agonism is weak but real [10]. Women with a history of estrogen receptor-positive breast cancer or those taking tamoxifen should discuss resveratrol with their oncologist before adding it, independent of any Jardiance interaction.

What Pharmacists and Guidelines Say

The Natural Medicines database (formerly Natural Standard) rates the resveratrol-SGLT2 inhibitor combination as a "minor" interaction based on additive glucose-lowering potential, with a recommendation to monitor blood glucose. The 2024 American Diabetes Association Standards of Medical Care in Diabetes state: "Herbal and dietary supplements are not recommended as routine additions to diabetes therapy due to lack of evidence supporting efficacy and concerns about safety interactions with antidiabetic agents" [16]. That is a general caution, not a specific prohibition against resveratrol plus empagliflozin, but it reflects the evidence gap.

Resveratrol is classified as Generally Recognized as Safe (GRAS) by the FDA for use as a food ingredient [18]. That designation applies to food-level exposures, not the gram-range doses found in some supplements.